PE17397A1 - Compuesto trans-dermico en parche del 3-[4-(hexiloxi)-1,2,5-tiadiazol-3-il]-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) - Google Patents
Compuesto trans-dermico en parche del 3-[4-(hexiloxi)-1,2,5-tiadiazol-3-il]-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina)Info
- Publication number
- PE17397A1 PE17397A1 PE1996000080A PE00008096A PE17397A1 PE 17397 A1 PE17397 A1 PE 17397A1 PE 1996000080 A PE1996000080 A PE 1996000080A PE 00008096 A PE00008096 A PE 00008096A PE 17397 A1 PE17397 A1 PE 17397A1
- Authority
- PE
- Peru
- Prior art keywords
- xanomelin
- matrix
- patch
- hexiloxi
- tiadiazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
CARACTERIZADO PORQUE EN UNA PRIMERA REALIZACION COMPRENDE: DE 0,1% A 35% P/P CON RESPECTO A LA MATRIZ DE XANOMELINA COMO INGREDIENTE ACTIVO; DE 0,1% A 10% CON RESPECTO A LA MATRIZ, DE AZONA COMO VEHICULO QUE FACILITA LA PENETRACION; DE 30% A 69,8% P/P DE ETANOL; DE 29% A 50% P/P DE AGUA; DE 2,5% A 3,5% P/P DE KLUCEL HF COMO AGENTE GELIFICADOR; Y OPCIONALMENTE HASTA UN 30% DE PROPILENGLICOL Y EN UNA SEGUNDA REALIZACION COMPRENDE: DE 85% A 97% P/P DE ETANOL Y DE 2% A 15% P/P DE KLUCEL HF; ESTANDO CADA COMPOSICION DISTRIBUIDA EN UNA MATRIZ, QUE COMPRENDE UN ADHESIVO CONSTITUIDO POR POLIMEROS Y COPOLIMEROS DE ESTERES DE ALQUILO DEL ACIDO ACRILICO Y EL ACIDO METAACRILICO (C1-C18), ENTRE OTROS Y SI ES ADHESIVO DE ACRILATO SE ENCUENTRA DE 88% A 99,8% P/P. LA FORMULACION TRANSDERMICA EN PARCHE PROPORCIONA UNA DOSIFICACION CONSISTENTE, REDUCIENDO LOS EFECTOS PARASIMPATICOMIMETICOS INDESEABLES EN TRATAMIENTOS TALES COMO ENFERMEDAD DE ALZHEIMER Y CONDICIONES DOLOROSAS SEVERAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38047895A | 1995-01-30 | 1995-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE17397A1 true PE17397A1 (es) | 1997-05-21 |
Family
ID=23501315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1996000080A PE17397A1 (es) | 1995-01-30 | 1996-02-02 | Compuesto trans-dermico en parche del 3-[4-(hexiloxi)-1,2,5-tiadiazol-3-il]-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5980933A (es) |
| EP (1) | EP0723781A3 (es) |
| JP (1) | JPH10513181A (es) |
| KR (1) | KR19980701730A (es) |
| AR (1) | AR001790A1 (es) |
| AU (1) | AU709379B2 (es) |
| BR (1) | BR9600216A (es) |
| CA (1) | CA2210711A1 (es) |
| CO (1) | CO4700420A1 (es) |
| CZ (1) | CZ240297A3 (es) |
| EA (1) | EA001083B1 (es) |
| HU (1) | HUP9800832A3 (es) |
| IL (1) | IL116895A (es) |
| NO (1) | NO973471L (es) |
| NZ (1) | NZ301197A (es) |
| PE (1) | PE17397A1 (es) |
| PL (1) | PL321686A1 (es) |
| RO (1) | RO117146B1 (es) |
| TR (1) | TR199700711T1 (es) |
| TW (1) | TW304167B (es) |
| WO (1) | WO1996023463A1 (es) |
| YU (1) | YU5196A (es) |
| ZA (1) | ZA96530B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090829A (en) * | 1996-08-01 | 2000-07-18 | Eli Lilly And Company | Method for treating excessive aggression |
| US6043258A (en) * | 1996-08-01 | 2000-03-28 | Eli Lilly And Company | Method for treating disruptive behavior disorders with xanomeline |
| US6117890A (en) * | 1996-08-01 | 2000-09-12 | Eli Lilly And Company | Method for treating bipolar disorder |
| EP0821956A1 (en) * | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Method for treating disruptive behavior disorders |
| EP0821954A1 (en) * | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Method for treating mental retardation |
| US6034108A (en) * | 1997-07-28 | 2000-03-07 | Eli Lilly And Company | Method for treating mental retardation |
| US6193993B1 (en) * | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| JP5106715B2 (ja) * | 1999-09-24 | 2012-12-26 | アルロン・ジャパン株式会社 | Ｌ−アスコルビン酸、ｌ−アスコルビン酸誘導体の皮膚真皮層への放出方法に使用するための組成物 |
| US7691404B2 (en) * | 2000-11-06 | 2010-04-06 | Samyang Corporation | Transdermal delivery system of diclofenac with improved water absorbability and adhesion properties |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| DE102005050431A1 (de) * | 2005-10-21 | 2007-04-26 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe |
| US20070259859A1 (en) * | 2006-05-04 | 2007-11-08 | De Bruin Natasja M W J | Muscarinic agonists to treat impulse control disorders |
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| US8846740B2 (en) | 2011-01-04 | 2014-09-30 | Biological Responsibility, Llc | Biotherapeutics for the treatment of infectious diseases |
| EP3265067A4 (en) * | 2015-03-06 | 2018-09-12 | Chase Pharmaceuticals Corporation | Oxybutynin-xanomeline transdermal therapeutic system combinations |
| WO2017044693A1 (en) | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4316893A (en) * | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4908027A (en) * | 1986-09-12 | 1990-03-13 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
| US5344656A (en) * | 1986-09-12 | 1994-09-06 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
| MY102980A (en) * | 1986-10-31 | 1993-03-31 | Pfizer | Transdermal flux enhancing compositions |
| DE3871464D1 (de) * | 1987-08-28 | 1992-07-02 | Lilly Co Eli | Die permeation verbessernde zusammensetzung. |
| IT1233860B (it) * | 1988-02-08 | 1992-04-21 | Isf Spa | Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa |
| DE3843239C1 (es) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| US5043345A (en) * | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| DK198590D0 (da) * | 1990-08-21 | 1990-08-21 | Novo Nordisk As | Heterocykliske forbindelser, deres fremstilling og anvendelse |
| US5238933A (en) * | 1991-10-28 | 1993-08-24 | Sri International | Skin permeation enhancer compositions |
-
1995
- 1995-02-17 TW TW084101515A patent/TW304167B/zh active
-
1996
- 1996-01-16 PL PL96321686A patent/PL321686A1/xx unknown
- 1996-01-16 WO PCT/US1996/000504 patent/WO1996023463A1/en not_active Application Discontinuation
- 1996-01-16 AU AU46565/96A patent/AU709379B2/en not_active Ceased
- 1996-01-16 RO RO97-01416A patent/RO117146B1/ro unknown
- 1996-01-16 TR TR97/00711T patent/TR199700711T1/xx unknown
- 1996-01-16 JP JP8523556A patent/JPH10513181A/ja active Pending
- 1996-01-16 EA EA199700151A patent/EA001083B1/ru not_active IP Right Cessation
- 1996-01-16 CA CA002210711A patent/CA2210711A1/en not_active Abandoned
- 1996-01-16 NZ NZ301197A patent/NZ301197A/en unknown
- 1996-01-16 CZ CZ972402A patent/CZ240297A3/cs unknown
- 1996-01-16 HU HU9800832A patent/HUP9800832A3/hu unknown
- 1996-01-16 KR KR1019970705126A patent/KR19980701730A/ko not_active Application Discontinuation
- 1996-01-22 ZA ZA96530A patent/ZA96530B/xx unknown
- 1996-01-25 IL IL11689596A patent/IL116895A/xx active IP Right Grant
- 1996-01-25 BR BR9600216A patent/BR9600216A/pt active Search and Examination
- 1996-01-25 EP EP96300535A patent/EP0723781A3/en not_active Withdrawn
- 1996-01-25 CO CO96003054A patent/CO4700420A1/es unknown
- 1996-01-26 AR AR33519696A patent/AR001790A1/es not_active Application Discontinuation
- 1996-01-29 YU YU5196A patent/YU5196A/sh unknown
- 1996-02-02 PE PE1996000080A patent/PE17397A1/es not_active Application Discontinuation
-
1997
- 1997-07-28 NO NO973471A patent/NO973471L/no not_active Application Discontinuation
- 1997-09-29 US US08/942,141 patent/US5980933A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RO117146B1 (ro) | 2001-11-30 |
| ZA96530B (en) | 1997-07-23 |
| TW304167B (es) | 1997-05-01 |
| EP0723781A3 (en) | 1996-08-07 |
| JPH10513181A (ja) | 1998-12-15 |
| CZ240297A3 (cs) | 1998-04-15 |
| HUP9800832A2 (hu) | 1999-01-28 |
| PL321686A1 (en) | 1997-12-22 |
| IL116895A0 (en) | 1996-05-14 |
| KR19980701730A (ko) | 1998-06-25 |
| BR9600216A (pt) | 1998-01-06 |
| CO4700420A1 (es) | 1998-12-29 |
| EA001083B1 (ru) | 2000-10-30 |
| EP0723781A2 (en) | 1996-07-31 |
| TR199700711T1 (xx) | 1998-01-21 |
| EA199700151A1 (ru) | 1997-12-30 |
| IL116895A (en) | 2000-08-31 |
| AR001790A1 (es) | 1997-12-10 |
| NO973471D0 (no) | 1997-07-28 |
| YU5196A (sh) | 1998-08-14 |
| US5980933A (en) | 1999-11-09 |
| WO1996023463A1 (en) | 1996-08-08 |
| AU709379B2 (en) | 1999-08-26 |
| AU4656596A (en) | 1996-08-21 |
| MX9705723A (es) | 1997-11-29 |
| NO973471L (no) | 1997-09-19 |
| CA2210711A1 (en) | 1996-08-08 |
| NZ301197A (en) | 1999-09-29 |
| HUP9800832A3 (en) | 2000-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE17397A1 (es) | Compuesto trans-dermico en parche del 3-[4-(hexiloxi)-1,2,5-tiadiazol-3-il]-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) | |
| CN102573843B (zh) | 含有多奈哌齐的经皮吸收型制剂 | |
| CY1120513T1 (el) | Υψηλης συμπυκνωσης συνθεση μινοξιδιλης | |
| MX9202328A (es) | Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo. | |
| AR070887A1 (es) | Composiciones farmaceuticas acuosas que contienen complejos de borato - poliol | |
| GT200000038A (es) | Inhibidores de la sorbitol deshidrogenasa. | |
| ES2091441T3 (es) | Composicion farmaceutica. | |
| DK302782A (da) | Anvendelse af eucalypol til at foroege et praeparats optagelse gennem huden | |
| CL2004001182A1 (es) | Composicion farmaceutica que comprende a una microparticula de liberacion sostenida la que contiene a un derivado de 1,2 benzazol; procedimiento de preparacion de la microparticula; util como broncodilatador, antipsicoticos y en otros problemas del s | |
| RU2004106779A (ru) | Способ профилактики и/или лечения дисфункции и/или нарушения структуры ногтей, пластырь для его осуществления и его применение | |
| ES2059786T3 (es) | Composicion blanqueante. | |
| PE20020505A1 (es) | Grupos quinuclidina sustituidos con heteroarilo para el tratamiento de enfermedades | |
| PA8452601A1 (es) | Tratamiento de la resistencia a la insulina | |
| AR026197A1 (es) | Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina | |
| DE69229318T2 (de) | Hydrierte Rizinusöl-enthaltende injizierbare Formulierungen mit verlängerter Wirkstoffabgabe | |
| CO4700408A1 (es) | Formulaciones transdermicas para un tiadiazolil-azabiclico [2.2.2] octano | |
| PE20010303A1 (es) | Nueva preparacion y forma de presentacion que contiene un agente activo labil en medio acido que consiste en un inhibidor de la bomba de protones labil en medio acido | |
| ES2169566T3 (es) | Composicion con acido azelaico. | |
| PE17997A1 (es) | Formulacion transdermica en parche del 3-[3-(hexiltio-1,2,5-tiadiazol-4-ilo]-1,2,5,6 tetrahidro-1-metil piridina | |
| AR006892A1 (es) | Uso de formas del acido hialuronico (ha) para el tratamiento del cancer | |
| AR002743A1 (es) | Esmalte de unas, y la utilizacion de dicho esmalte para la preparacion de un medicamento para el tratamiento de onicomicosis. | |
| ES2134237T3 (es) | Composiciones farmaceuticas que contienen acido ursodesoxicolico. | |
| IT1196041B (it) | Emichetali di (8s)-8-fluoroeritromicine,il procedimento per la loro preparazione e le formulazioni adatte alla somministrazione orale che contengono i prodotti | |
| SE8101374L (sv) | Kompositioner innehallande n,n-dietyl-m-toluamid | |
| PE12098A1 (es) | Composiciones y metodos para tratar transtornos respiratorios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |